Business
In this episode of Denatured, you’ll be listening to Jane Hughes, President of R&D and Co-founder of Verdiva Bio, and Jon Rees, CEO and Co-founder of MitoRx Therapeutics. We’ll discuss next-generation obesity solutions tackling GLP-1’s muscle loss and adherence challenges, through innovative muscle preservation, oral administration and combination therapy.
FEATURED STORIES
An analysis finds that pharmas frequently file multiple similar patents on drugs, then use them as the basis for questionable litigation against would-be competitors.
The limited supply of this common reagent is set to drive drug prices higher, but there are ways for companies to lessen the impact.
Suppliers are investing in production to support deals with AstraZeneca, Bayer and other drugmakers that are advancing radioisotope-based cancer therapies.
Subscribe to BioPharm Executive
Market insights and trending stories for biopharma leaders, in your inbox every Wednesday
THE LATEST
Acorda Therapeutics is reducing its staff count by 15% effective immediately as it struggles to bring operating costs down and hit expected revenue.
Biopharma and life sciences companies strengthen their leadership teams and boards with these Movers & Shakers.
Los Altos, Calif.-based Evommune closed on a Series A financing round worth $83 million. The financing round included Andera Partners, LSP, Pivotal bioVenture Partners.
The partnership combines the companies’ resources to focus on Axiomer, a technology that can edit single nucleotides in RNA in a specific and highly targeted manner.
Biopharma and life sciences companies from across the globe provide updates on their pipelines and businesses.
Norovirus vaccine is being developed at a rapid pace. HilleVax invests $135 million to rapidly progress the development. Here’s more about the vaccine.
Replicate focuses on using self-replicating RNA (srRNA) to develop therapies for autoimmune and inflammatory diseases and prevent drug resistance in cancer.
Elizabeth Holmes heads to court today to face multiple criminal fraud charges that could land the Theranos founder and CEO in prison for more than a decade.
Boston-based Ginkgo Bioworks has been having a banner year and doesn’t show any signs of stopping with its recent string of collaboration announcements.
Last spring he joined Fountain Therapeutics as CEO, a company that merges artificial intelligence (AI) with machine learning (ML) to develop therapeutics for degenerative diseases.